EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Open Access · CC BY-NC 4.0

Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis

Madeline Sanders iD, Eunjin Hong iD, Peter S Chung iD, Adupa P Rao iD, Paul Beringer iD

Clinical Pharmacokinetics · 2024

DOI: 10.1007/s40262-024-01440-w ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Madeline Sanders und 4 weiteren Autor:innen. Beteiligte Einrichtung: Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Biological Availability, Cystic Fibrosis, Tetracyclines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDCR NIH HHS, Paratek Pharmaceuticals, Inc., University of Southern California.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Omadacycline offers a potential advancement in the management of infections in people with cystic fibrosis (CF) because of its spectrum of activity, intrapulmonary penetration, and oral bioavailability. A prospective single-dose, single-arm study was conducted to characterize the pharmacokinetic (PK) profile of omadacycline in people with CF, considering the known alterations in PK observed in this population (NCT04460586, 2020-07-01). METHODS: Plasma samples were obtained from nine adults with CF who received a single dose of intravenous omadacycline 100 mg over 0.5 h followed by a 1-week washout and an oral dose of omadacycline 300 mg. The data were analyzed using noncompartmental PK. RESULTS: The maximum plasma concentration (Cmax) and area under the curve extrapolated to infinity (AUC0-∞) after intravenous administration of omadacycline were similar between healthy volunteers and people with CF. The absorption kinetics of oral omadacycline, encompassing both the rate (Cmax and time to Cmax [tmax]) and the extent (AUC0-∞), also showed consistency between healthy volunteers and people with CF. The absolute bioavailability of the oral tablet formulation of omadacycline in people with CF (31.2%) was also consistent with that observed in healthy volunteers (34.5%). In comparing the two routes of administration, intravenous omadacycline 100 mg provided plasma exposures equivalent to those with oral omadacycline 300 mg in people with CF, as evidenced by geometric mean ratios for both AUC0-∞ (0.9381; 90% confidence intervals [CI] 0.6783-1.2975) and Cmax (0.7746; 90% CI 0.5478-1.0951). CONCLUSIONS: Overall, the similarity in plasma PK observed in this study when comparing healthy volunteers and infected patients indicates that no dosing alterations are necessary when using omadacycline in people with CF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBiological AvailabilityCystic FibrosisTetracyclinesAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, IntravenousAdministration, OralArea Under CurveProspective Studies

Substanzen

Anti-Bacterial AgentsomadacyclineTetracyclines

Autor:innen und Institutionen

  • Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
  • College of Pharmacy, CHA University, Seongnam-si, South Korea.
  • Division of Pulmonary and Clinical Care Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Anton Yelchin CF Clinic, University of Southern California, Los Angeles, CA, USA.
  • Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA. beringer@usc.edu.
  • Anton Yelchin CF Clinic, University of Southern California, Los Angeles, CA, USA. beringer@usc.edu.

ORCID-Profile: Madeline Sanders, Eunjin Hong, Peter S Chung, Adupa P Rao, Paul Beringer

Förderung

  • NIDCR NIH HHS
  • Paratek Pharmaceuticals, Inc.
  • University of Southern California

Zitieren

APA

Sanders, M., Hong, E., Chung, P. S., Rao, A. P., & Beringer, P. (2024). Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01440-w

Vancouver

Sanders M, Hong E, Chung PS, Rao AP, Beringer P. Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-024-01440-w

BibTeX
@article{Sanders2024,
  author = {Sanders, Madeline and Hong, Eunjin and Chung, Peter S and Rao, Adupa P and Beringer, Paul},
  title = {Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis},
  journal = {Clinical Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s40262-024-01440-w}
}
Kostenlos starten →